Phuoc T. Tran, M.D., Ph.D.

Peer-Reviewed Articles

1. Sutera P, Van der Eecken K, Song Y, Shetty AC, Davicioni E, Proudfoot JA, Hakansson A, English K, Wang J, Guler OC, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Hathout L, Ennis R, Jabbour SK, Saraiya B, Stephenson R, Mayer T, Mishra M, Rana Z, Molitoris J, Kiess A, Song DY, DeWeese T, Pienta KJ, Tran PT, Berlin A, Onal C, Ost P, Deek MP. Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy. Eur Urol Oncol, 2025. e-Pub 2025. PMID: 40976747.
2. Singh A, Mendes WS, Oh SB, Guler OC, Elmali A, Demirhan B, Sawant A, Tran P, Onal C, Ren L. Prediction of metastasis-free survival in patients with localized prostate adenocarcinoma using primary tumor and lymph node radiomics from pre-treatment PSMA-PET/CT scans. Radiother Oncol 212:111119, 2025. e-Pub 2025. PMID: 40921333.
3. McAndrews KM, Paradiso F, Stalnecker CA, Chellakkan BS, Thege FI, Peng DH, Moreno Diaz BA, Sugimoto H, Patel SI, Mahadevan KK, Kirtley ML, Wills D, Sockwell AM, Fonseca ALF, Liu Y, Rajapakshe KI, Yee NG, Tran PT, Omar HA, Tedeschi A, Schischlik-Siegl F, Boghossian AS, Rees MG, Ronan MM, Roth JA, Rudolph D, Aichinger M, Ebner F, Artemov AV, Lipp J, Pisarsky L, Herrmann VL, Park J, Rippmann JF, Schaaf O, Chandler V, Williams M, Deckard CE, Wang L, Der CJ, Vellano C, Guerrero PA, Heffernan TP, Kalluri R, Maitra A. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Sci Transl Med 17(814):eadt5511, 2025. e-Pub 2025. PMID: 40901924.
4. Lafargue A, Wang H, Chettiar ST, Gajula RP, Shetty AC, Song Y, Simons BW, Khan MA, Nguyen T, Tseng HW, Chang J, Waters DN, Chan A, Lam C, Carrieri FA, Smack C, Connis N, Chowdhury DD, Nugent K, Siddiqui I, Taparra K, Rezaee M, Zachara N, Morris ZS, McFarland C, Abdulkadir SA, Hann CL, Tran PT. Twist1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of Twist1. Neoplasia 66:101179, 2025. e-Pub 2025. PMID: 40409044.
5. Phillips RM, Proudfoot JA, Davicioni E, Liu Y, Spratt DE, Simko JM, Den RB, Pollack A, Rosenthal SA, Sartor AO, Sweeney CJ, Attard G, Longoria L, Patel S, Straza MW, Efstathiou JA, Shah AB, Hoffman KE, Rodgers JP, Sandler HM, Feng FY, Tran PT. Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial. Eur Urol Oncol 8(4):968-976, 2025. e-Pub 2025. PMID: 40675873.
6. Sherry AD, Siddiqui BA, Haymaker C, Fellman BM, Medina-Rosales MN, Bathala TK, Wang S, Liu S, Seo A, Hara K, Lu H, Troncoso P, Chun SG, Ha CS, Mayo LL, Mok H, Park RJ, Chapin BF, Phillips RM, Deek MP, Kovitz CA, Aparicio A, Zurita AJ, Pilie PG, Cohen L, Choi SL, Reuben A, Tran PT, Corn PG, Subudhi SK, Tang C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol, 2025. e-Pub 2025. PMID: 40750497.
7. Parker CTA, Mendes L, Liu VYT, Grist E, Joun S, Yamashita R, Mitani A, Chen E, Parry MA, Sachdeva A, Murphy L, Huang HC, Griffin J, van der Wal D, Todorovic T, Lall S, Santos Vidal S, Goncalves M, Thakali S, Wingate A, Zakka L, Brown M, Wetterskog D, Amos CL, Atako NB, Jones RJ, Cross WR, Gillessen S, Parker CC, Berney DM, Tran PT, Spratt DE, Sydes MR, Parmar MKB, Clarke NW, Brown LC, Feng FY, Esteva A, James ND, Attard G. External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol. Lancet Digit Health 7(7):100885, 2025. e-Pub 2025. PMID: 40467357.
8. Wang JH, Sherry AD, Bazyar S, Sutera P, Radwan N, Phillips RM, Deek MP, Lu J, Dipasquale S, Deville C, DeWeese TL, Song DY, Wang H, Hobbs RF, Malek R, Dudley SA, Greco SC, Antonarakis ES, Marshall CH, Denmeade S, Paller CJ, Carducci MA, Pienta KJ, Oz OK, Ramotar M, Leenstra JL, Park SS, Abramowitz MC, Desai N, Berlin A, Stish BJ, Tang C, Tran PT, Kiess AP. Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. J Clin Oncol 43(18):2059-2068, 2025. e-Pub 2025. PMID: 40334149.
9. Cai L, Wu F, Zhou Q, Gao Y, Yao B, DeBerardinis RJ, Acquaah-Mensah GK, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Gruner BM, Jia D, Jones RA, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz C, MacPherson D, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll HP, Moorehead RA, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos M, Snyder EL, Sotillo R, Su KY, Taki T, Taparra K, Tran PT, Xia Y, van Veen JE, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, Minna JD. The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models. Cancer Res 85(10):1769-1783, 2025. e-Pub 2025. PMID: 40298430.
10. Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schar C, Berlin AM, Zwahlen DR, Simko JP, Holscher T, Efstathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SG. Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials. Ann Oncol 36(5):572-582, 2025. e-Pub 2025. PMID: 39986927.
11. Roach M 3rd, Zhang J, Mohamad O, van der Wal D, Simko JP, DeVries S, Huang HC, Joun S, Schaeffer EM, Morgan TM, Keim-Malpass J, Chen E, Yamashita R, Monson JM, Naz F, Wallace J, Bahary JP, Wilke D, Batra S, Biedermann GB, Faria S, Hwang L, Sandler HM, Spratt DE, Pugh SL, Esteva A, Tran PT, Feng FY. Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials. JCO Clin Cancer Inform 9:e2400284, 2025. e-Pub 2025. PMID: 40344545.
12. Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL. Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. J Clin Oncol:JCO2400365, 2025. e-Pub 2025. PMID: 40239134.
13. Andrews JR, Kim Y, Horjeti E, Arafa A, Gunn H, De Bruycker A, Phillips R, Song D, Childs DS, Sartor OA, Orme JJ, Chaudhuri AA, Tran P, Kiess A, Sutera P, Mercier C, Ost P, Park SS, Lucien F. PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts. Clin Cancer Res 31(6):1142-1149, 2025. e-Pub 2025. PMID: 39820657.
14. Onal C, Elmali A, Erbay G, Demirhan B, Sutera P, Deek MP, Tran PT, Guler OC. Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients. Prostate 85(4):344-353, 2025. e-Pub 2025. PMID: 39616524.
15. Sutera P, Song Y, Shetty AC, English K, Van der Eecken K, Guler OC, Wang J, Cao Y, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Kiess A, Song DY, DeWeese T, Pienta KJ, Barbieri C, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Tran PT, Ost P, Deek MP. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol 8(1):111-118, 2025. e-Pub 2025. PMID: 38862340.
16. Ling X, Bazyar S, Ferris M, Molitoris J, Allor E, Thomas H, Arons D, Schumaker L, Krc R, Mendes WS, Tran PT, Sawant A, Mehra R, Gaykalova DA, Ren L. Identification of CT based radiomic biomarkers for progression free survival in head and neck squamous cell carcinoma. Sci Rep 15(1):1279, 2025. e-Pub 2025. PMID: 39779914.
17. Wang JH, Deek MP, Mendes AA, Song Y, Shetty A, Bazyar S, Van der Eecken K, Chen E, Showalter TN, Royce TJ, Todorovic T, Huang HC, Houck SA, Yamashita R, Kiess AP, Song DY, Lotan T, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Esteva A, Feng FY, Tran PT, Sutera P, Ost P. Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer. Radiother Oncol 202:110618, 2025. e-Pub 2025. PMID: 39510141.
18. Deek MP, Sutera P, Jing Y, Gao R, Rothman E, Day H, Chang D, Dirix P, Armstrong AJ, Campbell B, Lopez Campos F, Berenguer M, Ramotar M, Conde-Moreno A, Berlin A, Bosetti DG, Corcoran N, Koontz B, Mercier C, Siva S, Pryor D, Ost P, Huynh MA, Kroeze S, Stish B, Kiess A, Trock B, Tran PT, Gillessen S, Sweeney C. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol 7(6):1403-1410, 2024. e-Pub 2024. PMID: 38570239.
19. Do TA, Tran PM, Vu TH, Tran HK, Nguyen HQ, Nguyen LD, Nguyen HT, Van Nguyen C. Real-world Efficacy and Safety of Low-Dose Abiraterone With Food and Standard-Dose Abiraterone in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis. Clin Genitourin Cancer 22(6):102191, 2024. e-Pub 2024. PMID: 39226637.
20. Alexander GS, Krc RF, Assif JW, Sun K, Molitoris JK, Tran P, Rana Z, Mishra MV. Conditional Risk and Predictive Factors Associated With Late Toxicity in Patients With Prostate Cancer Treated With External Beam Radiation Therapy Alone in the Randomized Trial RTOG 0126. Int J Radiat Oncol Biol Phys 120(4):990-998, 2024. e-Pub 2024. PMID: 38825251.
21. Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY. Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. Eur Urol Oncol, 2024. e-Pub 2024. PMID: 39542826.
22. Onal C, Guler OC, Torun N, Elmali A, Sutera P, Deek MP, Reyhan M, Yavuz M, Tran PT. Impact of definitive radiotherapy on metabolic response measured with (68)Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer. Prostate 84(15):1366-1374, 2024. e-Pub 2024. PMID: 39107926.
23. Lang Y, Jiang Z, Sun L, Tran P, Mossahebi S, Xiang L, Ren L. Patient-specific deep learning for 3D protoacoustic image reconstruction and dose verification in proton therapy. Med Phys 51(10):7425-7438, 2024. e-Pub 2024. PMID: 38980065.
24. Cao Y, Sutera P, Silva Mendes W, Yousefi B, Hrinivich T, Deek M, Phillips R, Song D, Kiess A, Cem Guler O, Torun N, Reyhan M, Sawant A, Marchionni L, Simone NL, Tran P, Onal C, Ren L. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics. Radiother Oncol 199:110443, 2024. e-Pub 2024. PMID: 39094629.
25. Sutera P, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Tran PT, Deek MP. PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer. Prostate 84(14):1301-1308, 2024. e-Pub 2024. PMID: 39021052.
26. Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben A, Gomella LG, Sartor AO, Rosenthal SA, Sandler HM, Spratt DE, Pugh SL, Mohamad O, Esteva A, Chen E, Schaeffer EM, Tran PT, Feng FY. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial. Eur Urol Oncol 7(5):1024-1033, 2024. e-Pub 2024. PMID: 38302323.
27. Tran PT. Management of oligometastatic hormone-sensitive prostate cancer. Clin Adv Hematol Oncol 22(8):370-373, 2024. e-Pub 2024. PMID: 39356815.
28. Rana Z, Kamran SC, Shetty AC, Sutera P, Song Y, Bazyar S, Solanki AA, Simko JP, Pollack A, McConkey D, Kates M, Siddiqui MM, Hiken J, Earls J, Messina D, Mouw KW, Miyamoto D, Shipley WU, Michaelson MD, Zietman A, Coen JJ, Dahl DM, Jani AB, Souhami L, Chang BK, Lee RJ, Pham H, Marshall DT, Shen X, Pugh SL, Feng FY, Efstathiou JA, Tran PT, Deek MP. Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712. Eur Urol Oncol 7(5):986-989, 2024. e-Pub 2024. PMID: 38641541.
29. Deng Z, Xu X, Dehghani H, Reyes J, Zheng L, Tran PT, Wang KK. In vivo bioluminescence tomography-guided system for pancreatic cancer radiotherapy research. Biomed Opt Express 15(8):4525-4539, 2024. e-Pub 2024. PMID: 39347008.
30. Onal C, Guler OC, Erpolat P, Hurmuz P, Sutera P, Deek MP, Elmali A, Yilmaz MT, Koken UH, Yavuz M, Ozyigit G, Tran PT. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging. Clin Nucl Med 49(8):e383-e389, 2024. e-Pub 2024. PMID: 38847441.
31. Krc R, Mendes W, Molitoris J, Ferris M, Song Y, Shetty A, Mehra R, Papadimitriou JC, Hatten K, Taylor R, Wolf J, Sun K, Bentzen S, Regine W, Tran P, Witek M. Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer. Oral Oncol 154:106875, 2024. e-Pub 2024. PMID: 38824813.
32. Sutera P, Deek MP, Deek RA, Guler OC, Hurmuz P, Reyhan M, Rowe S, Radwan N, Dipasquale S, Hrinivich WT, Lowe K, Ren L, Saraiya B, Ennis R, Hathout L, Mayer T, Deweese TL, Song DY, Kiess A, Oymak E, Pienta K, Feng F, Pomper M, Ozyigit G, Tran PT, Onal C, Phillips RM. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer. Adv Radiat Oncol 9(7):101507, 2024. e-Pub 2024. PMID: 38799104.
33. Tran PTC, Thellman CJ, Woolf K, Hamid A, Rice-Stitt TL. Rare melanosis in the urinary bladder and prostate: a case report. J Surg Case Rep 2024(5):rjae269, 2024. e-Pub 2024. PMID: 38706479.
34. Nguyen T, Carrieri FA, Connis N, Lafargue A, Chang J, Chan A, Shetty AC, Song Y, Hoang T, Jagtap S, Chowdhury DD, Khan MA, Gabrielson KL, Rezaee M, Torres-Ayuso P, Brognard J, Hann CL, Tran PT. TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy. Mol Cancer Ther 23(8):1201-11, 2024. e-Pub 2024. PMID: 38670554.
35. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol 211(4):509-517, 2024. e-Pub 2024. PMID: 38421253.
36. Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, Rana Z, Pienta K, Feng F, Song DY, DeWeese T, Gillessen S, Sweeney C, James N, Attard G, Deek M, Tran PT. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol 7(2):241-247, 2024. e-Pub 2024. PMID: 37558543.
37. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol 211(4):526-532, 2024. e-Pub 2024. PMID: 38421252.
38. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol 211(4):518-525, 2024. e-Pub 2024. PMID: 38421243.
39. Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus 10(2):271-278, 2024. e-Pub 2024. PMID: 38307806.
40. Kishan AU, Siva S, Hofman MS, Nagarajah J, Kiess AP, Tran P, Calais J. The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease. J Nucl Med, 2024. e-Pub 2024. PMID: 38360048.
41. Hoang T, Sutera P, Nguyen T, Chang J, Jagtap S, Song Y, Shetty AC, Chowdhury DD, Chan A, Carrieri FA, Hathout L, Ennis R, Jabbour SK, Parikh R, Molitoris J, Song DY, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Lafargue A, Van Der Eecken K, Bunz F, Ost P, Tran PT, Deek MP. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment. Prostate 84(1):87-99, 2024. e-Pub 2024. PMID: 37812042.
42. Ling X, Alexander GS, Molitoris J, Choi J, Schumaker L, Tran P, Mehra R, Gaykalova D, Ren L. Radiomic biomarkers of locoregional recurrence: prognostic insights from oral cavity squamous cell carcinoma preoperative CT scans. Front Oncol 14:1380599, 2024. e-Pub 2024. PMID: 38715772.
43. Meiller TF, Fraser CM, Grant-Beurmann S, Humphrys M, Tallon L, Sadzewicz LD, Jabra-Rizk MA, Alfaifi A, Kensara A, Molitoris JK, Witek M, Mendes WS, Regine WF, Tran PT, Miller RC, Sultan AS. A Longitudinal Metagenomic Comparative Analysis of Oral Microbiome Shifts in Patients Receiving Proton Radiation versus Photon Radiation for Head and Neck Cancer. J Cancer Allied Spec 10(1):579, 2024. e-Pub 2024. PMID: 38259673.
44. Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, Rana Z, Ren L, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Song DY, Pienta K, Feng FY, Joniau S, Lotan T, Lane B, Kiess A, Rowe S, Pomper M, DeWeese T, Deek M, Sweeney C, Ost P, Tran PT. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol 84(6):531-535, 2023. e-Pub 2023. PMID: 37173210.
45. Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys 117(2):370-377, 2023. e-Pub 2023. PMID: 37137444.
46. Voong KR, Illei PB, Presson B, Singh D, Zeng Z, Lanis M, Hales RK, Hu C, Tran PT, Georgiades C, Lin CT, Thiboutout J, Brahmer JR, Forde PM, Naidoo J, Anagnostou V, Smith KN. Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective stud. J Immunother Cancer 11(10), 2023. e-Pub 2023. PMID: 37793854.
47. Alexander GS, Krc RF, Assif JW, Sun K, Molitoris JK, Tran P, Rana Z, Bentzen SM, Mishra MV. Conditional Risks of Biochemical Failure and Prostate Cancer-Specific Death in Patients Undergoing External Beam Radiotherapy: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Netw Open 6(9):e2335069, 2023. e-Pub 2023. PMID: 37751207.
48. Bazyar S, Sutera P, Deek MP, Marshall CH, Tran PT. Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer. EBioMedicine 95:104756, 2023. e-Pub 2023. PMID: 37566929.
49. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid 2(8):EVIDoa2300023, 2023. e-Pub 2023. PMID: 38320143.
50. Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, Lee Kiang Chua M, Sweeney CJ, Schaeffer EM. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer 129(14):2169-2178, 2023. e-Pub 2023. PMID: 37060201.
51. Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra AD, de Meerleer G, Eade T, Haustermans K, Holscher T, Hocht S, Ghadjar P, Davicioni E, Heck M, Kerkmeijer LGW, Kirste S, Tselis N, Tran PT, Pinkawa M, Pommier P, Deltas C, Schmidt-Hegemann NS, Wiegel T, Zilli T, Tree AC, Qiu X, Murthy V, Epstein JI, Graztke C, Gao X, Grosu AL, Kamran SC, Zamboglou C. Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus. Int J Radiat Oncol Biol Phys 116(3):503-520, 2023. e-Pub 2023. PMID: 36596346.
52. Valenzi E, Bahudhanapati H, Tan J, Tabib T, Sullivan DI, Nouraie M, Sembrat J, Fan L, Chen K, Liu S, Rojas M, Lafargue A, Felsher DW, Tran PT, Kass DJ, Lafyatis R. Single-nucleus chromatin accessibility identifies a critical role for TWIST1 in idiopathic pulmonary fibrosis myofibroblast activity. Eur Respir J 62(1), 2023. e-Pub 2023. PMID: 37142338.
53. Sutera PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, Chang J, Fonteyne V, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Rana Z, Hodges T, Hamid A, Roberts N, Song DY, Pienta K, Ross AE, Feng F, Joniau S, Spratt D, Gillessen S, Attard G, James ND, Lotan T, Davicioni E, Sweeney C, Tran PT, Deek MP, Ost P. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol 34(7):605-614, 2023. e-Pub 2023. PMID: 37164128.
54. Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol 83(6):486-494, 2023. e-Pub 2023. PMID: 36717286.
55. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. Res Sq, 2023. e-Pub 2023. PMID: 37131691.
56. Wang X, Raman N, Lemtiri-Chlieh G, Chang J, Jagtap S, Chowdhury DD, Ballew M, Carrieri FA, Nguyen T, Nugent K, Peck T, Levine MS, Chan A, Lam C, Malek R, Hoang T, Phillips R, Cheng Z, Taparra K, Connis N, Hann CL, Holland A, Tran PT, Lafargue A, Wang H. Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS. Mol Cancer Ther 22(4):519-528, 2023. e-Pub 2023. PMID: 36752776.
57. Sutera P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, Song Y, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, Tran PT. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys 115(5):1095-1101, 2023. e-Pub 2023. PMID: 36708787.
58. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys 115(3):645-653, 2023. e-Pub 2023. PMID: 36179990.
59. Sheng JY, Snyder CF, Smith KC, DeSanto J, Mayonado N, Rall S, White S, Blackford AL, Johnston FM, Joyner RL Jr, Mischtschuk J, Peairs KS, Thorner E, Tran PT, Wolff AC, Choi Y. Evaluating potential overuse of surveillance care in cancer survivors. Cancer Med 12(5):6139-6147, 2023. e-Pub 2023. PMID: 36369671.
60. Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, Denmeade S, Carducci M, Eisenberger M, DeWeese TL, Orton M, Deville C, Davicioni E, Liauw SL, Heath EI, Greco S, Desai NB, Spratt DE, Feng F, Wang H, Beer TM, Antonarakis ES. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol 41(6):1307-1317, 2023. e-Pub 2023. PMID: 36367998.
61. Lee EE, Singh T, Hu C, Han M, Deville CJ, Halthore A, Greco S, Tran P, DeWeese T, Song DY. The impact of salvage radiotherapy initiation at PSA
62. Wang S, Ryan Russell J, Drescher M, Park A, Legesse T, Kundra V, Tran PT, Phelan M, Naslund M, Minhaj Siddiqui M. Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy. Prostate 82(16):1520-1528, 2022. e-Pub 2022. PMID: 35923127.
63. Sjostrom M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res 82(21):3888-3902, 2022. e-Pub 2022. PMID: 36251389.
64. Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol 40(29):3377-3382, 2022. e-Pub 2022. PMID: 36001857.
65. Smith KC, White S, DeSanto J, Hannum S, Mayonado N, Ahuja N, Bowie J, Cowall D, Mischtschuk J, Peairs K, Thorner E, Tran P, Wolff A, Snyder C. Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial. J Cancer Surviv 16(4):791-800, 2022. e-Pub 2022. PMID: 34296383.
66. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 5(1):71, 2022. e-Pub 2022. PMID: 35676445.
67. Reyes DK, Trock BJ, Tran PT, Pavlovich CP, Deville C, Allaf ME, Greco SC, Song DY, Bivalacqua TJ, Han M, Partin AW, Sartor AO, Rowe SP, Pienta KJ. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Med Oncol 39(5):63, 2022. e-Pub 2022. PMID: 35478055.
68. Zhang Z, Huang M, Jiang Z, Chang Y, Lu K, Yin FF, Tran P, Wu D, Beltran C, Ren L. Patient-specific deep learning model to enhance 4D-CBCT image for radiomics analysis. Phys Med Biol 67(8), 2022. e-Pub 2022. PMID: 35313293.
69. Cao Y, Song DY, Deville C, DeWeese TL, Greco S, Tran PT, Deek MP. Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?. Prostate 82(5):551-555, 2022. e-Pub 2022. PMID: 35014708.
70. Sutera P, Van Der Eecken K, Kishan AU, Hamid A, Grist E, Attard G, Lotan T, Mendes AA, Paller CJ, Carducci MA, Ross A, Wang H, Pienta K, Feng FY, Antonarakis ES, Ost P, Song DY, Greco S, Deville C, DeWeese T, Tran PT, Deek MP. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer Prostatic Dis 25(4):713-719, 2022. e-Pub 2022. PMID: 35013522.
71. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol 8(3):e216871, 2022. e-Pub 2022. PMID: 35050303.
72. Sutera P, Phillips RM, Deek M, Ozyigit G, Onal C, Tran PT. The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging. J Nucl Med 63(3):339-341, 2022. e-Pub 2022. PMID: 35058322.
73. Kishan AU, Marco N, Schulz-Jaavall MB, Steinberg ML, Tran PT, Juarez JE, Dang A, Telesca D, Lilleby WA, Weidhaas JB. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiother Oncol 167:226-232, 2022. e-Pub 2022. PMID: 34990726.
74. Lombardo KA, Obradovic A, Singh AK, Liu JL, Joice G, Kates M, Bishai W, McConkey D, Chaux A, Eich ML, Rezaei MK, Netto GJ, Drake CG, Tran P, Matoso A, Bivalacqua TJ. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. J Pathol 256(2):223-234, 2022. e-Pub 2022. PMID: 34731491.
75. Snyder C, Choi Y, Blackford AL, DeSanto J, Mayonado N, Rall S, White S, Bowie J, Cowall DE, Johnston F, Joyner RL, Mischtschuk J, Peairs KS, Thorner E, Tran PT, Wolff AC, Smith KC. Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches. J Natl Cancer Inst 114(1):139-148, 2022. e-Pub 2022. PMID: 34302474.
76. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open 4(12):e2138550, 2021. e-Pub 2021. PMID: 34902034.
77. Van der Eecken K, Vanwelkenhuyzen J, Deek MP, Tran PT, Warner E, Wyatt AW, Kwan EM, Verbeke S, Van Dorpe J, Fonteyne V, Lumen N, De Laere B, Ost P. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. Eur Urol Oncol 4(6):914-923, 2021. e-Pub 2021. PMID: 34801437.
78. Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P, Tran PT. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Eur Urol 80(5):632-640, 2021. e-Pub 2021. PMID: 33419682.
79. Hamid AA, Huang HC, Wang V, Chen YH, Feng F, Den R, Attard G, Van Allen EM, Tran PT, Spratt DE, Dittamore R, Davicioni E, Liu G, DiPaola R, Carducci MA, Sweeney CJ. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol 32(9):1157-1166, 2021. e-Pub 2021. PMID: 34129855.
80. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol 80(2):142-146, 2021. e-Pub 2021. PMID: 33985797.
81. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open 4(7):e2115312, 2021. e-Pub 2021. PMID: 34196715.
82. Deek MP, Taparra K, Phillips R, Velho PI, Gao RW, Deville C, Song DY, Greco S, Carducci M, Eisenberger M, DeWeese TL, Denmeade S, Pienta K, Paller CJ, Antonarakis ES, Olivier KR, Park SS, Tran PT, Stish BJ. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. Eur Urol Oncol 4(3):447-455, 2021. e-Pub 2021. PMID: 32536574.
83. Choi Y, Smith KC, Shukla A, Blackford AL, Tran PT, Peairs KS, DeMarco TM, Choflet A, Farling K, Kelso M, Carducci MA, Mayonado N, Snyder CF. What are survivorship care plans failing to tell men after prostate cancer treatment?. Prostate 81(7):398-406, 2021. e-Pub 2021. PMID: 33755233.
84. Eguiarte-Solomon F, Blazanin N, Rho O, Carbajal S, Felsher DW, Tran PT, DiGiovanni J. Twist1 is required for the development of UVB-induced squamous cell carcinoma. Mol Carcinog 60(5):342-353, 2021. e-Pub 2021. PMID: 33713497.
85. Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol 7(4):544-552, 2021. e-Pub 2021. PMID: 33570548.
86. Marshall CH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, Sartor O, Antonarakis ES. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 27(6):1623-1630, 2021. e-Pub 2021. PMID: 33451978.
87. Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol 79(3):374-383, 2021. e-Pub 2021. PMID: 33293078.
88. Deek MP, Taparra K, Dao D, Chan L, Phillips R, Gao RW, Kwon ED, Deville C, Song DY, Greco S, Carducci MA, Eisenberger M, DeWeese TL, Denmeade S, Pienta K, Paller CJ, Antonarakis ES, Olivier KR, Park SS, Stish BJ, Tran PT. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys 109(2):387-395, 2021. e-Pub 2021. PMID: 32798608.
89. De Bruycker A, Tran PT, Achtman AH, Ost P. Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries. World J Urol 39(2):317-326, 2021. e-Pub 2021. PMID: 31955223.
90. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys 109(1):174-185, 2021. e-Pub 2021. PMID: 32861817.
91. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, Briganti A, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, Spratt DE. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol 6(12):1912-1920, 2020. e-Pub 2020. PMID: 33090219.
92. Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys 108(4):917-926, 2020. e-Pub 2020. PMID: 32544574.
93. Deek M, Lilleby W, Vaage V, Hole KH, DeWeese T, Stensvold A, Tran P, Seierstad T. Impact of radiation dose on recurrence in high-risk prostate cancer patients. Prostate 80(15):1322-1327, 2020. e-Pub 2020. PMID: 33258482.
94. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol 78(3):327-332, 2020. e-Pub 2020. PMID: 32461072.
95. Padmanaban V, Grasset EM, Neumann NM, Fraser AK, Henriet E, Matsui W, Tran PT, Cheung KJ, Georgess D, Ewald AJ. Organotypic culture assays for murine and human primary and metastatic-site tumors. Nat Protoc 15(8):2413-2442, 2020. e-Pub 2020. PMID: 32690957.
96. Wright JL, Alcorn SR, McNutt T, Han-Oh S, Gonzalez R, Lin L, Anderson R, Wieworka J, Deville C, Ladra M, Meyer J, Hales R, Voong R, Narang A, Vogel J, Asrari F, Kiess A, Song D, Tran P, Kleinberg L, Redmond K, Tsien C, Quon H, Page B, Croog V, Walker A, Greco S, Laiho M, Viswanathan A. An Integrated Program in a Pandemic: Johns Hopkins Radiation Oncology Department. Adv Radiat Oncol 5(4):666-672, 2020. e-Pub 2020. PMID: 32292844.
97. Reyes DK, Rowe SP, Schaeffer EM, Allaf ME, Ross AE, Pavlovich CP, Deville C, Tran PT, Pienta KJ. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Med Oncol 37(7):60, 2020. e-Pub 2020. PMID: 32524295.
98. Hasan H, Deek MP, Phillips R, Hobbs RF, Malek R, Radwan N, Kiess AP, Dipasquale S, Huang J, Caldwell T, Leitzel J, Wendler D, Wang H, Thompson E, Powell J, Dudley S, Deville C, Greco SC, Song DY, DeWeese TL, Gorin MA, Rowe SP, Denmeade S, Markowski M, Antonarakis ES, Carducci MA, Eisenberger MA, Pomper MG, Pienta KJ, Paller CJ, Tran PT. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer 20(1):492, 2020. e-Pub 2020. PMID: 32487038.
99. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 6(5):650-659, 2020. e-Pub 2020. PMID: 32215577.
100. Hrinivich WT, Phillips R, Da Silva AJ, Radwan N, Gorin MA, Rowe SP, Pienta KJ, Pomper MG, Wong J, Tran PT, Kang-Hsin Wang K. Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer. Adv Radiat Oncol 5(2):260-268, 2020. e-Pub 2020. PMID: 32280826.
101. Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, Neal TO, Chapman C, Harb R, Milman Y, Trock BJ, Drake CG, Antonarakis ES. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis 23(1):184-193, 2020. e-Pub 2020. PMID: 31611635.
102. Deng Z, Xu X, Dehghani H, Reyes J, Zheng L, Klose AD, Wong JW, Tran PT, Wang KK. In vivo bioluminescence tomography-guided radiation research platform for pancreatic cancer: an initial study using subcutaneous and orthotopic pancreatic tumor models. Proc SPIE Int Soc Opt Eng 11224, 2020. e-Pub 2020. PMID: 33223595.
103. Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Rajan Kd A, Lai I, Gabay M, Tong L, Krishnan M, Park J, Hu T, Barbhuiya MA, Gentles AJ, Kannan K, Tran PT, Felsher DW. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Elife 9, 2020. e-Pub 2020. PMID: 31933479.
104. Deek MP, Phillips R, Tran PT. Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer: What Is the Standard of Care?. Cancer J 26(1):87-93, 2020. e-Pub 2020. PMID: 31977391.
105. Peng LC, Mian OY, Lakshminarayanan P, Huang P, Bae HJ, Robertson S, Habtu T, Narang A, Agarwal S, Greco S, Tran P, McNutt T, DeWeese TL, Song DY. Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. Urology 135:111-116, 2020. e-Pub 2020. PMID: 31454660.
106. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol 77(1):3-10, 2020. e-Pub 2020. PMID: 30992160.
107. Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, Tran PT. Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. Int J Radiat Oncol Biol Phys 105(5):948-956, 2019. e-Pub 2019. PMID: 31419509.
108. Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol 37(12):2623-2629, 2019. e-Pub 2019. PMID: 30191396.
109. Shokoohmand A, Ren J, Baldwin J, Atack A, Shafiee A, Theodoropoulos C, Wille ML, Tran PA, Bray LJ, Smith D, Chetty N, Pollock PM, Hutmacher DW, Clements JA, Williams ED, Bock N. Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts. Biomaterials 220:119402, 2019. e-Pub 2019. PMID: 31400612.
110. Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. Eur Urol 76(2):170-176, 2019. e-Pub 2019. PMID: 30293905.
111. Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, Heath EI, Liauw S, Spratt DE, Hung AY, Antonarakis ES, Tran PT. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer 19(1):572, 2019. e-Pub 2019. PMID: 31196032.
112. Gomez E, Tran PT, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. Clin Nucl Med 44(4):e313-e314, 2019. e-Pub 2019. PMID: 30789396.
113. Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W. Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Urol Oncol 37(4):289.e19-289.e26, 2019. e-Pub 2019. PMID: 30446451.
114. Gupta M, Patel HD, Schwen ZR, Tran PT, Partin AW. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. BJU Int 123(2):252-260, 2019. e-Pub 2019. PMID: 29626845.
115. Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, Rudin CM, Tran PT, Burns TF. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene 38(5):656-670, 2019. e-Pub 2019. PMID: 30171258.
116. Bock N, Shokoohmand A, Kryza T, Rohl J, Meijer J, Tran PA, Nelson CC, Clements JA, Hutmacher DW. Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment. Bone Res 7:13, 2019. e-Pub 2019. PMID: 31044095.
117. Wang H, Tran PT. Author's view: epithelial plasticity metabolically reprograms normal cells towards a neoplastic-prone state. Mol Cell Oncol 6(1):1543485, 2019. e-Pub 2019. PMID: 30788419.
118. Jafarnejad M, Sove RJ, Danilova L, Mirando AC, Zhang Y, Yarchoan M, Tran PT, Pandey NB, Fertig EJ, Popel AS. Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. NPJ Syst Biol Appl 5:29, 2019. e-Pub 2019. PMID: 31452933.
119. Taparra K, Wang H, Malek R, Lafargue A, Barbhuiya MA, Wang X, Simons BW, Ballew M, Nugent K, Groves J, Williams RD, Shiraishi T, Verdone J, Yildirir G, Henry R, Zhang B, Wong J, Wang KK, Nelkin BD, Pienta KJ, Felsher D, Zachara NE, Tran PT. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. J Clin Invest 128(11):4924-4937, 2018. e-Pub 2018. PMID: 30130254.
120. Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 128(9):3926-3940, 2018. e-Pub 2018. PMID: 29952768.
121. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys 101(4):883-888, 2018. e-Pub 2018. PMID: 29976500.
122. Shah VP, Lakshminarayanan P, Moore J, Tran PT, Quon H, Deville C, McNutt TR. Data integrity systems for organ contours in radiation therapy planning. J Appl Clin Med Phys 19(4):58-67, 2018. e-Pub 2018. PMID: 29893465.
123. Peng LC, Narang AK, Gergis C, Radwan NA, Han P, Marciscano AE, Robertson SP, He P, Trieu J, Ram AN, McNutt TR, Griffith E, DeWeese TA, Honig S, Singh H, Greco SC, Tran PT, Deville C, DeWeese TL, Song DY. Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy. Urol Oncol 36(6):309.e7-309.e14, 2018. e-Pub 2018. PMID: 29551548.
124. Hayman J, Phillips R, Chen D, Perin J, Narang AK, Trieu J, Radwan N, Greco S, Deville C Jr, McNutt T, Song DY, DeWeese TL, Tran PT. Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality. Prostate 78(8):623-630, 2018. e-Pub 2018. PMID: 29520847.
125. Kishan AU, Tendulkar RD, Tran PT, Parker CC, Nguyen PL, Stephenson AJ, Carrie C. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. Eur Urol Oncol 1(1):3-18, 2018. e-Pub 2018. PMID: 31100226.
126. Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ. The Future of Radiobiology. J Natl Cancer Inst 110(4):329-340, 2018. e-Pub 2018. PMID: 29126306.
127. Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, Miller R, Nugent K, Shinder B, Tosoian J, Fuchs EJ, Tran PT, Hurley PJ, Vuica-Ross M, Schaeffer EM, Drake CG, Ross AE. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis 21(1):126-136, 2018. e-Pub 2018. PMID: 29556048.
128. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA 319(9):896-905, 2018. e-Pub 2018. PMID: 29509865.
129. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 73(2):156-165, 2018. e-Pub 2018. PMID: 28716370.
130. Marciscano AE, Walker JM, McGee HM, Kim MM, Kunos CA, Monjazeb AM, Shiao SL, Tran PT, Ahmed MM. Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop. J Immunother Cancer 6(1):6, 2018. e-Pub 2018. PMID: 29375032.
131. Heerma van Voss MR, Vesuna F, Bol GM, Afzal J, Tantravedi S, Bergman Y, Kammers K, Lehar M, Malek R, Ballew M, Ter Hoeve N, Abou D, Thorek D, Berlinicke C, Yazdankhah M, Sinha D, Le A, Abrahams R, Tran PT, van Diest PJ, Raman V. Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment. Oncogene 37(1):63-74, 2018. e-Pub 2018. PMID: 28869602.
132. Phillips RM, Gorin MA, Rowe SP, Pomper MG, Pienta KJ, Ross AE, Tran PT. Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. Urol Case Rep 16:86-88, 2018. e-Pub 2018. PMID: 29226093.
133. Maxwell R, Luksik AS, Garzon-Muvdi T, Hung AL, Kim ES, Wu A, Xia Y, Belcaid Z, Gorelick N, Choi J, Theodros D, Jackson CM, Mathios D, Ye X, Tran PT, Redmond KJ, Brem H, Pardoll DM, Kleinberg LR, Lim M. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncoimmunology 7(12):e1500108, 2018. e-Pub 2018. PMID: 30524891.
134. Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, Wang H, Attar MA, Huang EH, Chatley SN, Nugent K, Somasundaram A, Engh JA, Ewald AJ, Cho YJ, Rudin CM, Tran PT, Burns TF. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Mol Cancer Res 15(12):1764-1776, 2017. e-Pub 2017. PMID: 28851812.
135. Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, Wenzel A, Hicks J, Ballew M, Stone M, Tran PT, Zahnow CA, Hellmann MD, Anagnostou V, Strissel PL, Strick R, Velculescu VE, Baylin SB. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell 171(6):1284-1300.e21, 2017. e-Pub 2017. PMID: 29195073.
136. Barbhuiya MA, Mirando AC, Simons BW, Lemtiri-Chlieh G, Green JJ, Popel AS, Pandey NB, Tran PT. Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. Oncotarget 8(60):101520-101534, 2017. e-Pub 2017. PMID: 29254183.
137. Kates M, Chappidi MR, Brant A, Milbar N, Sopko NA, Meyer C, Terezakis SA, Herman JM, Efron JE, Safar B, Tran PT, Ahuja N, Pierorazio PM, Bivalacqua TJ. High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. Bladder Cancer 3(3):191-199, 2017. e-Pub 2017. PMID: 28824947.
138. Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer 17(1):453, 2017. e-Pub 2017. PMID: 28662647.
139. Malek R, Gajula RP, Williams RD, Nghiem B, Simons BW, Nugent K, Wang H, Taparra K, Lemtiri-Chlieh G, Yoon AR, True L, An SS, DeWeese TL, Ross AE, Schaeffer EM, Pienta KJ, Hurley PJ, Morrissey C, Tran PT. TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Res 77(12):3181-3193, 2017. e-Pub 2017. PMID: 28484075.
140. Narang AK, Trieu J, Radwan N, Ram A, Robertson SP, He P, Gergis C, Griffith E, Singh H, DeWeese TA, Honig S, Annadanam A, Greco S, DeVille C, McNutt T, DeWeese TL, Song DY, Tran PT. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 20(2):203-209, 2017. e-Pub 2017. PMID: 28094250.
141. Tosoian JJ, Alam R, Gergis C, Narang A, Radwan N, Robertson S, McNutt T, Ross AE, Song DY, DeWeese TL, Tran PT, Walsh PC. Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease. Prostate Cancer Prostatic Dis 20(2):193-196, 2017. e-Pub 2017. PMID: 28045113.
142. Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, Schaeffer EM, Drake CG, Feng F, Ross AE. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 20(1):28-35, 2017. e-Pub 2017. PMID: 27801901.
143. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, Mathios D, Jackson CM, Harris-Bookman S, Garzon-Muvdi T, Sheu M, Martin AM, Tyler BM, Tran PT, Ye X, Olivi A, Taube JM, Burger PC, Drake CG, Brem H, Pardoll DM, Lim M. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res 23(1):124-136, 2017. e-Pub 2017. PMID: 27358487.
144. Tran PT, Antonarakis ES. Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion. J Oncol Pract 13(1):21-24, 2017. e-Pub 2017. PMID: 28045614.
145. Zhang B, Wong JW, Iordachita II, Reyes J, Nugent K, Tran PT, Tuttle SW, Koumenis C, Wang KK. Evaluation of On- and Off-Line Bioluminescence Tomography System for Focal Irradiation Guidance. Radiat Res 186(6):592-601, 2016. e-Pub 2016. PMID: 27869556.
146. Xie M, Vesuna F, Tantravedi S, Bol GM, Heerma van Voss MR, Nugent K, Malek R, Gabrielson K, van Diest PJ, Tran PT, Raman V. RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3. Cancer Res 76(21):6340-6350, 2016. e-Pub 2016. PMID: 27634756.
147. Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis 19(3):277-82, 2016. e-Pub 2016. PMID: 27136742.
148. Chettiar ST, Malek R, Annadanam A, Nugent KM, Kato Y, Wang H, Cades JA, Taparra K, Belcaid Z, Ballew M, Manmiller S, Proia D, Lim M, Anders RA, Herman JM, Tran PT. Ganetespib radiosensitization for liver cancer therapy. Cancer Biol Ther 17(4):457-66, 2016. e-Pub 2016. PMID: 26980196.
149. Zhang B, Wang KK, Yu J, Eslami S, Iordachita I, Reyes J, Malek R, Tran PT, Patterson MS, Wong JW. Bioluminescence Tomography-Guided Radiation Therapy for Preclinical Research. Int J Radiat Oncol Biol Phys 94(5):1144-53, 2016. e-Pub 2016. PMID: 26876954.
150. Narang AK, Tran PT. Prostate cancer: Case volume and improved outcomes across cancer care. Nat Rev Urol 13(4):186-7, 2016. e-Pub 2016. PMID: 26832160.
151. Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, Weiss MJ, Wolfgang CL, Ford E, Grossman SA, Ye X, Ellsworth SG. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 94(3):571-9, 2016. e-Pub 2016. PMID: 26867885.
152. Armstrong AJ, Halabi S, Healy P, Lee WR, Koontz BF, Moul JW, Mundy K, Creel P, Wood S, Davis K, Carducci MA, Stein M, Hobbs C, Reimer B, Nguyen M, Anand M, Bratt L, Kim S, Tran PT, George DJ. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis 19(1):100-6, 2016. e-Pub 2016. PMID: 26754260.
153. Narang AK, Gergis C, Robertson SP, He P, Ram AN, McNutt TR, Griffith E, DeWeese TA, Honig S, Singh H, Song DY, Tran PT, DeWeese TL. Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. Int J Radiat Oncol Biol Phys 94(2):254-62, 2016. e-Pub 2016. PMID: 26853334.
154. Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer 4:28, 2016. e-Pub 2016. PMID: 27190629.
155. Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Radiat Oncol 10:232, 2015. e-Pub 2015. PMID: 26577452.
156. Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 38(3):259-65, 2015. e-Pub 2015. PMID: 23648440.
157. Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, Bellovin DI, Tran PT, Philbrick WM, Garcia-Ocana A, Casey SC, Li Y, Dang CV, Zare RN, Felsher DW. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A 112(21):6539-44, 2015. e-Pub 2015. PMID: 25964345.
158. Bol GM, Vesuna F, Xie M, Zeng J, Aziz K, Gandhi N, Levine A, Irving A, Korz D, Tantravedi S, Heerma van Voss MR, Gabrielson K, Bordt EA, Polster BM, Cope L, van der Groep P, Kondaskar A, Rudek MA, Hosmane RS, van der Wall E, van Diest PJ, Tran PT, Raman V. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med 7(5):648-69, 2015. e-Pub 2015. PMID: 25820276.
159. Wild AT, Dholakia AS, Fan KY, Kumar R, Moningi S, Rosati LM, Laheru DA, Zheng L, De Jesus-Acosta A, Ellsworth SG, Hacker-Prietz A, Voong KR, Tran PT, Hruban RH, Pawlik TM, Wolfgang CL, Herman JM. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J Gastrointest Oncol 6(2):115-25, 2015. e-Pub 2015. PMID: 25830031.
160. Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, Wang H, Malek R, Taparra K, Cades J, Annadanam A, Yoon AR, Fertig E, Firulli BA, Mazzacurati L, Burns TF, Firulli AB, An SS, Tran PT. Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells. Neoplasia 17(1):16-31, 2015. e-Pub 2015. PMID: 25622896.
161. Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. Clin Cancer Res 20(24):6406-17, 2014. e-Pub 2014. PMID: 25326230.
162. Huynh-Le MP, Zhang Z, Tran PT, DeWeese TL, Song DY. Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists. Int J Radiat Oncol Biol Phys 90(5):1076-82, 2014. e-Pub 2014. PMID: 25442040.
163. Alcorn SR, Gocke CD, Woodard CA, Tran PT. Solitary plasmacytoma of the penile urethra treated with primary radiotherapy. J Clin Oncol 32(28):e95-7, 2014. e-Pub 2014. PMID: 24516036.
164. Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ. Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate 74(6):628-36, 2014. e-Pub 2014. PMID: 24453066.
165. Sengupta S, Weeraratne SD, Sun H, Phallen J, Rallapalli SK, Teider N, Kosaras B, Amani V, Pierre-Francois J, Tang Y, Nguyen B, Yu F, Schubert S, Balansay B, Mathios D, Lechpammer M, Archer TC, Tran P, Reimer RJ, Cook JM, Lim M, Jensen FE, Pomeroy SL, Cho YJ. alpha5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol 127(4):593-603, 2014. e-Pub 2014. PMID: 24196163.
166. Shamir ER, Pappalardo E, Jorgens DM, Coutinho K, Tsai WT, Aziz K, Auer M, Tran PT, Bader JS, Ewald AJ. Twist1-induced dissemination preserves epithelial identity and requires E-cadherin. J Cell Biol 204(5):839-56, 2014. e-Pub 2014. PMID: 24590176.
167. Fan KY, Dholakia AS, Wild AT, Su Z, Hacker-Prietz A, Kumar R, Hodgin M, Hsu CC, Le DT, De Jesus-Acosta A, Diaz LA Jr, Laheru DA, Hruban RH, Fishman EK, Brown TD, Pawlik TM, Wolfgang CL, Tran PT, Herman JM. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. J Natl Compr Canc Netw 12(1):50-7, 2014. e-Pub 2014. PMID: 24453292.
168. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C, Albesiano E, Durham NM, Ye X, Tran PT, Tyler B, Wong JW, Brem H, Pardoll DM, Drake CG, Lim M. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 9(7):e101764, 2014. e-Pub 2014. PMID: 25013914.
169. Dholakia AS, Kumar R, Raman SP, Moore JA, Ellsworth S, McNutt T, Laheru DA, Jaffee E, Cameron JL, Tran PT, Hobbs RF, Wolfgang CL, Herman JM. Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design. Int J Radiat Oncol Biol Phys 87(5):1007-15, 2013. e-Pub 2013. PMID: 24267969.
170. Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol 4(4):343-51, 2013. e-Pub 2013. PMID: 24294505.
171. Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, Chung CH, Rudin CM, Herman JM, Hales RK, Raman V, An SS, Tran PT. The twist box domain is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res 11(11):1387-400, 2013. e-Pub 2013. PMID: 23982216.
172. Hiniker SM, Roux A, Murphy JD, Harris JP, Tran PT, Kapp DS, Kidd EA. Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes. Gynecol Oncol 131(2):380-5, 2013. e-Pub 2013. PMID: 23954572.
173. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86(2):343-9, 2013. e-Pub 2013. PMID: 23462419.
174. Zeng J, Aziz K, Chettiar ST, Aftab BT, Armour M, Gajula R, Gandhi N, Salih T, Herman JM, Wong J, Rudin CM, Tran PT, Hales RK. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. Int J Radiat Oncol Biol Phys 86(1):143-9, 2013. e-Pub 2013. PMID: 23182391.
175. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tome W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract 9(3):e90-5, 2013. e-Pub 2013. PMID: 23942508.
176. Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, Aziz K, Cho YJ, Tran PT, Rudin CM. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Mol Cancer Res 11(4):329-38, 2013. e-Pub 2013. PMID: 23364532.
177. Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther 14(4):347-56, 2013. e-Pub 2013. PMID: 23358469.
178. Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol 31(7):886-94, 2013. e-Pub 2013. PMID: 23341531.
179. Wild AT, Gandhi N, Chettiar ST, Aziz K, Gajula RP, Williams RD, Kumar R, Taparra K, Zeng J, Cades JA, Velarde E, Menon S, Geschwind JF, Cosgrove D, Pawlik TM, Maitra A, Wong J, Hales RK, Torbenson MS, Herman JM, Tran PT. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. PLoS One 8(6):e65726, 2013. e-Pub 2013. PMID: 23762417.
180. Trakul N, Chang CN, Harris J, Chapman C, Rao A, Shen J, Quinlan-Davidson S, Filion EJ, Wakelee HA, Colevas AD, Whyte RI, Dieterich S, Maxim PG, Hristov D, Tran P, Le QT, Loo BW Jr, Diehn M. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys 84(1):231-7, 2012. e-Pub 2012. PMID: 22381907.
181. Daly ME, Kapp DS, Maxim PG, Welton ML, Tran PT, Koong AC, Chang DT. Orthovoltage intraoperative radiotherapy for locally advanced and recurrent colorectal cancer. Dis Colon Rectum 55(6):695-702, 2012. e-Pub 2012. PMID: 22595850.
182. Tseng D, Rachakonda LP, Su Z, Advani R, Horning S, Hoppe RT, Quon A, Graves EE, Loo BW Jr, Tran PT. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. Radiat Oncol 7:5, 2012. e-Pub 2012. PMID: 22260710.
183. Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, Withofs N, Sweet-Cordero A, Gambhir SS, Rudin CM, Felsher DW. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet 8(5):e1002650, 2012. e-Pub 2012. PMID: 22654667.
184. Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP, Schwartz LH, Miller VA, Kawashima T, Kitamura T, Paik D, Felsher DW. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 3(103):103ra99, 2011. e-Pub 2011. PMID: 21974937.
185. Zeng J, See AP, Aziz K, Thiyagarajan S, Salih T, Gajula RP, Armour M, Phallen J, Terezakis S, Kleinberg L, Redmond K, Hales RK, Salvatori R, Quinones-Hinojosa A, Tran PT, Lim M. Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biol Ther 12(7):657-63, 2011. e-Pub 2011. PMID: 21811091.
186. See AP, Zeng J, Tran PT, Lim M. Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series. Radiat Oncol 6:25, 2011. e-Pub 2011. PMID: 21414215.
187. Nielsen CH, Kimura RH, Withofs N, Tran PT, Miao Z, Cochran JR, Cheng Z, Felsher D, Kjaer A, Willmann JK, Gambhir SS. PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res 70(22):9022-30, 2010. e-Pub 2010. PMID: 21062977.
188. Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT. Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol 5:105, 2010. e-Pub 2010. PMID: 21059255.
189. Graves EE, Vilalta M, Cecic IK, Erler JT, Tran PT, Felsher D, Sayles L, Sweet-Cordero A, Le QT, Giaccia AJ. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res 16(19):4843-52, 2010. e-Pub 2010. PMID: 20858837.
190. Zhou H, Rodriguez M, van den Haak F, Nelson G, Jogani R, Xu J, Zhu X, Xian Y, Tran PT, Felsher DW, Keall PJ, Graves EE. Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals. Int J Radiat Oncol Biol Phys 78(1):297-305, 2010. e-Pub 2010. PMID: 20395069.
191. Chapman CH, Shen J, Filion EJ, Tran PT, Hara W, Asuncion A, Marko D, Wakelee H, Berry GJ, Dimmick KW, Loo BW Jr, Green J. Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir. J Thorac Oncol 4(12):1587-9, 2009. e-Pub 2009. PMID: 20009915.
192. Horoschak M, Tran PT, Bachireddy P, West RB, Mohler D, Beaulieu CF, Kapp DS, Donaldson SS. External beam radiation therapy enhances local control in pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 75(1):183-7, 2009. e-Pub 2009. PMID: 19211195.
193. Hara W, Tran P, Li G, Su Z, Puataweepong P, Adler JR Jr, Soltys SG, Chang SD, Gibbs IC. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery 64(2 Suppl):A26-32, 2009. e-Pub 2009. PMID: 19165071.
194. Tran PT, Felsher DW. The current STATe of biomarkers to predict the response to anti-angiogenic therapies. Cancer Biol Ther 7(12):2004-6, 2008. e-Pub 2008. PMID: 19158482.
195. Tran PT, Hara W, Su Z, Lin HJ, Bendapudi PK, Norton J, Teng N, King CR, Kapp DS. Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. Int J Radiat Oncol Biol Phys 72(4):1146-53, 2008. e-Pub 2008. PMID: 18394818.
196. Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One 3(5):e2125, 2008. e-Pub 2008. PMID: 18461184.
197. Tran PT, Fey JP, Erdeniz N, Gellon L, Boiteux S, Liskay RM. A mutation in EXO1 defines separable roles in DNA mismatch repair and post-replication repair. DNA Repair (Amst) 6(11):1572-83, 2007. e-Pub 2007. PMID: 17602897.
198. Tran PT, Su Z, Hara W, Husain A, Teng N, Kapp DS. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 69(2):504-11, 2007. e-Pub 2007. PMID: 17560736.
199. Tran PT, Su Z, Lee P, Lavori P, Husain A, Teng N, Kapp DS. Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 105(3):641-9, 2007. e-Pub 2007. PMID: 17363046.
200. Chugh SS, Senashova O, Watts A, Tran PT, Zhou Z, Gong Q, Titus JL, Hayflick SJ. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol 43(9):1625-9, 2004. e-Pub 2004. PMID: 15120823.
201. Tran PT, Erdeniz N, Dudley S, Liskay RM. Characterization of nuclease-dependent functions of Exo1p in Saccharomyces cerevisiae. DNA Repair (Amst) 1(11):895-912, 2002. e-Pub 2002. PMID: 12531018.
202. Welz-Voegele C, Stone JE, Tran PT, Kearney HM, Liskay RM, Petes TD, Jinks-Robertson S. Alleles of the yeast Pms1 mismatch-repair gene that differentially affect recombination- and replication-related processes. Genetics 162(3):1131-45, 2002. e-Pub 2002. PMID: 12454061.
203. Tran PT, Simon JA, Liskay RM. Interactions of Exo1p with components of MutLalpha in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 98(17):9760-5, 2001. e-Pub 2001. PMID: 11481425.
204. Bowers J, Tran PT, Joshi A, Liskay RM, Alani E. MSH-MLH complexes formed at a DNA mismatch are disrupted by the PCNA sliding clamp. J Mol Biol 306(5):957-68, 2001. e-Pub 2001. PMID: 11237611.
205. Bowers J, Tran PT, Liskay RM, Alani E. Analysis of yeast MSH2-MSH6 suggests that the initiation of mismatch repair can be separated into discrete steps. J Mol Biol 302(2):327-38, 2000. e-Pub 2000. PMID: 10970737.
206. Tran PT, Liskay RM. Functional studies on the candidate ATPase domains of Saccharomyces cerevisiae MutLalpha. Mol Cell Biol 20(17):6390-8, 2000. e-Pub 2000. PMID: 10938116.
207. Tran PT, Hori H, Hori Y, Okumura K, Kagotani K, Taguchi H, Carson DA, Nobori T. Molecular cloning of the human methylthioadenosine phosphorylase processed pseudogene and localization to 3q28. Gene 186(2):263-9, 1997. e-Pub 1997. PMID: 9074505.
208. Hori H, Tran P, Carrera CJ, Hori Y, Rosenbach MD, Carson DA, Nobori T. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 56(24):5653-8, 1996. e-Pub 1996. PMID: 8971171.
209. Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, Yu AL, Carson DA. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci U S A 93(12):6203-8, 1996. e-Pub 1996. PMID: 8650244.

Review Articles

1. Zamboglou C, Doncker W, Christoforou AT, Arcangeli S, Berlin A, Blanchard P, Bauman G, Campi R, Castro E, Choudhury A, Pra AD, Draulans C, Desai N, Ferentinos K, Francolini G, Gillessen S, Grosu AL, Rivas JG, Hoelscher T, Hruby G, Jereczek-Fossa BA, Kamran S, Kasivisvanathan V, Kishan AU, Kounnis V, Loblaw A, Martin J, Mastroleo F, Merseburger AS, Miszczyk M, Mohamad O, Ost P, Papatsoris A, Peeken JC, Sanguedolce F, Sargos P, Schmidt-Hegemann N, Seibert TM, Shelan M, Siva S, Soeterik TFW, Spratt DE, Stenzl A, Strouthos I, Sutera P, Supiot S, Tilki D, Tran PT, Tree AC, Tward J, Urun Y, Vapiwala N, Waddle MR, Wegener E, Zilli T, Murthy V, Thieme AH, Spohn S. oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus. Radiother Oncol 210:111039, 2025. e-Pub 2025. PMID: 40645505.
2. Wang JH, Shi X, Tran PT, Sutera P. Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer. PET Clin 20(2):205-217, 2025. e-Pub 2025. PMID: 39924369.
3. Bazyar S, Mannuel H, Tran PT. Stereotactic ablative radiation therapy in metastatic prostate cancer. Curr Opin Oncol 36(3):180-185, 2024. e-Pub 2024. PMID: 38362949.
4. Sutera P, Skinner H, Witek M, Mishra M, Kwok Y, Davicioni E, Feng F, Song D, Nichols E, Tran PT, Bergom C. Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology. Semin Radiat Oncol 33(3):232-242, 2023. e-Pub 2023. PMID: 37331778.
5. Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, Koontz B, De Meeleer G, Palma D, Ost P, Tran PT. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers. Eur Urol Oncol 6(1):28-38, 2023. e-Pub 2023. PMID: 36283936.
6. Sutera P, Deek MP, Van der Eecken K, Wyatt AW, Kishan AU, Molitoris JK, Ferris MJ, Siddiqui MM, Rana Z, Mishra MV, Kwok Y, Davicioni E, Spratt DE, Ost P, Feng FY, Tran PT. Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate 82 Suppl 1(Suppl 1):S73-S85, 2022. e-Pub 2022. PMID: 35657158.
7. Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Tree A, Turner S, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag JE, Morgans AK, Garcia JA, Showalter TN, Feng FY, Spratt DE. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 113(2):278-289, 2022. e-Pub 2022. PMID: 34923058.
8. Smith KC, Choi Y, Blackford AL, DeSanto J, Mayonado N, Rall S, White S, Bowie J, Hannum S, Johnston F, Joyner RL Jr, Mischtschuk J, Peairs KS, Thorner E, Tran PT, Wolff AC, Snyder CF, 2022. e-Pub 2022. PMID: 39666842.
9. Deek MP, Phillips RM, Tran PT. Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer. Semin Radiat Oncol 31(3):242-249, 2021. e-Pub 2021. PMID: 34090651.
10. Gutiontov SI, Pitroda SP, Tran PT, Weichselbaum RR. (Oligo)metastasis as a Spectrum of Disease. Cancer Res 81(10):2577-2583, 2021. e-Pub 2021. PMID: 33452011.
11. Marciscano AE, Haimovitz-Friedman A, Lee P, Tran PT, Tome WA, Guha C, Spring Kong FM, Sahgal A, El Naqa I, Rimner A, Marks LB, Formenti SC, DeWeese TL. Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. Int J Radiat Oncol Biol Phys 110(1):35-52, 2021. e-Pub 2021. PMID: 30836168.
12. Lam C, Low JY, Tran PT, Wang H. The hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategies. Cancer Lett 503:11-18, 2021. e-Pub 2021. PMID: 33484754.
13. Deek MP, Tran PT. Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer. Cancer J 26(2):137-143, 2020. e-Pub 2020. PMID: 32205538.
14. Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, Tran PT. Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment. Front Oncol 10:575992, 2020. e-Pub 2020. PMID: 33215030.
15. Phillips RM, Deek MP, Deweese TL, Tran PT. Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?. Oncology (Williston Park) 33(10), 2019. e-Pub 2019. PMID: 31661149.
16. Ahmad SS, Crittenden MR, Tran PT, Kluetz PG, Blumenthal GM, Bulbeck H, Baird RD, Williams KJ, Illidge T, Hahn SM, Lawrence TS, Spears PA, Walker AJ, Sharma RA. Clinical Development of Novel Drug-Radiotherapy Combinations. Clin Cancer Res 25(5):1455-1461, 2019. e-Pub 2019. PMID: 30498095.
17. Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC. What Is Oligometastatic Prostate Cancer?. Eur Urol Focus 5(2):159-161, 2019. e-Pub 2019. PMID: 30642810.
18. Phillips RM, Lam C, Wang H, Tran PT. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations. Adv Cancer Res 142:23-62, 2019. e-Pub 2019. PMID: 30885363.
19. Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, Sarkaria JN, Sondel PM, Tran PT, Wilson GD, Willers H, Wong RKS, Harari PM. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncol 19(5):e240-e251, 2018. e-Pub 2018. PMID: 29726389.
20. De Bleser E, Tran PT, Ost P. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol 27(6):587-595, 2017. e-Pub 2017. PMID: 28816714.
21. Nicholas S, Chen L, Choflet A, Fader A, Guss Z, Hazell S, Song DY, Tran PT, Viswanathan AN. Pelvic Radiation and Normal Tissue Toxicity. Semin Radiat Oncol 27(4):358-369, 2017. e-Pub 2017. PMID: 28865519.
22. Rowe SP, Tran PT, Fishman EK, Johnson PT. Oligoprogression: What Radiologists Need to Know About This Emerging Concept in Cancer Therapeutic Decision-making. Acad Radiol 24(7):898-900, 2017. e-Pub 2017. PMID: 28341411.
23. Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer 123(11):1912-1924, 2017. e-Pub 2017. PMID: 28323334.
24. Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14(1):15-25, 2017. e-Pub 2017. PMID: 27725639.
25. Malek R, Wang H, Taparra K, Tran PT. Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Cells Tissues Organs 203(2):114-127, 2017. e-Pub 2017. PMID: 28214899.
26. Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19(3):223-30, 2016. e-Pub 2016. PMID: 27136743.
27. Taparra K, Tran PT, Zachara NE. Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes. Front Oncol 6:85, 2016. e-Pub 2016. PMID: 27148477.
28. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 35 Suppl(Suppl):S276-S304, 2015. e-Pub 2015. PMID: 26590477.
29. Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A, Ashraf SS, Aquilano K, Azmi AS, Bhakta D, Bilsland A, Boosani CS, Chen S, Ciriolo MR, Fujii H, Guha G, Halicka D, Helferich WG, Keith WN, Mohammed SI, Niccolai E, Yang X, Honoki K, Parslow VR, Prakash S, Rezazadeh S, Shackelford RE, Sidransky D, Tran PT, Yang ES, Maxwell CA. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol 35 Suppl(Suppl):S5-S24, 2015. e-Pub 2015. PMID: 25869442.
30. Sharabi AB, Tran PT, Lim M, Drake CG, Deweese TL. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) 29(5):331-40, 2015. e-Pub 2015. PMID: 25979541.
31. Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES, Georgakilas AG. Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett 342(2):213-22, 2014. e-Pub 2014. PMID: 22634493.
32. Walker AJ, Alcorn SR, Narang AK, Nugent KM, Wild AT, Herman JM, Tran PT. Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. Curr Probl Cancer 37(5):301-12, 2013. e-Pub 2013. PMID: 24331186.
33. Alcorn S, Walker AJ, Gandhi N, Narang A, Wild AT, Hales RK, Herman JM, Song DY, Deweese TL, Antonarakis ES, Tran PT. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci 14(7):14800-32, 2013. e-Pub 2013. PMID: 23863691.
34. Zeng J, Harris TJ, Lim M, Drake CG, Tran PT. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int 2013:658126, 2013. e-Pub 2013. PMID: 24324970.
35. Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL. Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med 12(6):772-87, 2012. e-Pub 2012. PMID: 22292443.
36. Tran PT, Erdeniz N, Symington LS, Liskay RM. EXO1-A multi-tasking eukaryotic nuclease. DNA Repair (Amst) 3(12):1549-59, 2004. e-Pub 2004. PMID: 15474417.

Other Articles

1. Patel KR, Spratt DE, Tran PT, Krauss DJ, D'Amico AV, Nguyen PL The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 122(2):407-415, 2025. PMID: 39922318.
2. Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377. Int J Radiat Oncol Biol Phys 120(5):1461, 2024. PMID: 39320298.
3. Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, Wang H, Malek R, Taparra K, Cades J, Annadanam A, Yoon AR, Fertig E, Firulli BA, Mazzacurati L, Burns TF, Firulli AB, An SS, Tran PT Corrigendum to "Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells" [Neoplasia 17 (2014) 85]. Neoplasia 57:101010, 2024. PMID: 39389677.
4. Tward JD, Huang HC, Esteva A, Mohamad O, van der Wal D, Simko JP, DeVries S, Zhang J, Joun S, Showalter TN, Schaeffer EM, Morgan TM, Monson JM, Wallace JA, Bahary JP, Sandler HM, Spratt DE, Rodgers JP, Feng FY, Tran PT Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. JCO Precis Oncol 8:e2400145, 2024. PMID: 39447096.
5. Spratt DE, Liu VYT, Jia AY, Royce TJ, Sandler HM, Pugh SL, Tran PT, Feng FY Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials. Eur Urol 86(4):369-371, 2024. PMID: 39025748.
6. Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, Tran P, Feng FY Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. Int J Radiat Oncol Biol Phys 116(3):521-529, 2023. PMID: 36596347.
7. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 6(1):27, 2023. PMID: 36813827.
8. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol 77(2):201-208, 2020. PMID: 31718822.
9. . PMID: 23540490.

Editorials

1. Deek MP, Tran PT, Jabbour SK. Metastasis-Directed Therapy: A Moving Target Advancing Progress Forward. J Clin Oncol 42(1):4-7, 2024. PMID: 37748118.
2. Tran PT, Sutera P, Phillips RM, Deek MP, Chmura S. From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. Int J Radiat Oncol Biol Phys 114(4):576-580, 2022. PMID: 36244393.
3. Glicksman RM, Palma DA, Deek MP, Tsai CJ, Chmura S, Siva S, Ost P, Tran PT, Berlin A. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?. Int J Radiat Oncol Biol Phys 114(4):561-570, 2022. PMID: 36244387.
4. Solanki AA, Kates MR, Tran PT. Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001. Eur Urol 82(3):280-282, 2022. PMID: 35641349.
5. Tran PT, Ost P. Developments in oligometastatic hormone-sensitive prostate cancer. World J Urol 37(12):2545-2547, 2019. PMID: 31705198.
6. Deek MP, Phillips RM, Haffner M, Tran PT. Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?. Eur Urol 75(1):42-43, 2019. PMID: 30268657.
7. Phillips RM, Hayman J, Tran PT. STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer. J Clin Oncol 36(5):435-437, 2018. PMID: 29240543.
8. Phillips R, Ost P, Tran PT. What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?. Future Oncol 13(24):2121-2124, 2017. PMID: 29019420.
9. Tosoian JJ, Tran PT, Ross AE. Concurrent Androgen Deprivation with Radiotherapy: A Cautionary Tale of "Do As I Say, Not As I Do"?. Eur Urol 70(3):436-7, 2016. PMID: 27080744.
10. Tran PT, Bivalacqua TJ, Dicker AP. Adjuvant radiation for node-positive disease after prostatectomy: more good news, but who will listen?. J Clin Oncol 32(35):3917-9, 2014. PMID: 25311219.

Letters to the Editor

1. Tran PT, Mouw KW. SABR Today . . . and Tomorrow?. Int J Radiat Oncol Biol Phys 118: 11, 2024.
2. Deek MP, Stish BJ, Tran PT. In Reply to Onal et al. Int J Radiat Oncol Biol Phys 110: 1547-1548, 2021.
3. Tran PT, Deek MP, Phillips RM. Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold-Reply. JAMA Oncol 6: 1639, 2020.
4. Tran PT, Hayman J, Phillips RM. Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al. J Clin Oncol 36: 2352-2353, 2018.
5. Tran PT, Feng F, Ost P. Live to SABR Another Day?. Int J Radiat Oncol Biol Phys 100: 1097, 2018.
6. Tran PT, Bivalacqua TJ, Dicker AP. Reply to C.G. Rusthoven et al. J Clin Oncol 33: 1990-1, 2015.